We are live on ! Find out more
ATRS

Antares Pharma, Inc.
ATRS

Delisted

ATRS was delisted on the 23rd of May, 2022.

Back to rankings

159 hedge funds and large institutions have $195M invested in Antares Pharma, Inc. in 2020 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 57 increasing their positions, 45 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 14

27% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 45

24% more capital invested

Capital invested by funds: $157M → $195M (+$38.2M)

3% more funds holding

Funds holding: 154 → 159 (+5)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

19% less call options, than puts

Call options by funds: $311K | Put options by funds: $386K

Holders
159
Holders Change
+5
Holders Change %
+3.25%
% of All Funds
3.25%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
20
Increased
57
Reduced
45
Closed
14
Calls
$311K
Puts
$386K
Net Calls
-$75K
Net Calls Change
+$291K

Top Buyers

Rank Fund Capital Flow
1
CWM
Centric Wealth Management
Illinois
+$10M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$4.1M
3
ACM
Asymmetry Capital Management
California
+$3.63M
4
AQR Capital Management
AQR Capital Management
Connecticut
+$2.11M
5
State Street
State Street
Massachusetts
+$1.92M

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$3.15M
2
Morgan Stanley
Morgan Stanley
New York
-$2.56M
3
Millennium Management
Millennium Management
New York
-$2.12M
4
SCM
Soleus Capital Management
Connecticut
-$1.77M
5
SIG
Sargent Investment Group
Maryland
-$1.75M

ATRS Hedge Fund Activity: Q2 2020 in Review

159 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q2 2020, worth a combined $195M — up 24% from $157M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new ATRS positions and 14 closed out — a net gain of 6 holders — while 57 added to existing stakes and 45 trimmed.

The largest buyer was Centric Wealth Management, opening a new position worth an estimated $10M. The largest seller was Renaissance Technologies, cutting an estimated $3.15M.

  • 159 institutional investors held Antares Pharma, Inc. (ATRS) as of Q2 2020, up from 154 in Q1 2020.
  • Funds reported $195M of Antares Pharma, Inc. stock for Q2 2020, up 24% quarter-over-quarter.
  • 20 funds opened new Antares Pharma, Inc. positions in Q2 2020 and 14 closed out, a net change of +6 holders.
  • The largest Antares Pharma, Inc. buyer in Q2 2020 was Centric Wealth Management, an estimated $10M added.
  • The largest Antares Pharma, Inc. seller in Q2 2020 was Renaissance Technologies, an estimated $3.15M sold.

Based on aggregated 13F filings for Q2 2020.